Cytarabine & Midostaurin consolidation therapy for acute myeloid leukemia (AML)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Regimen in use at


FDA-recommended dose
Study Evidence
Stone et al. 2017 (RATIFY) Non-randomized portion of RCT

Preceding treatment


28-day cycle for 4 cycles

Subsequent treatment


  1. RATIFY: Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. Epub 2017 Jun 23. link to original article link to PMC article contains verified protocol PubMed